Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TYK2 | P29597 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | FLT1 | P17948 | 2/20 | 0.52 |
| ▸ | FLT4 | P35916 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.48 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407088 | 0.90 | MAPK1 (0.53) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL7091405 | 0.86 | RAB9A (0.65) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL13609519 | 0.86 | MAPK1 (0.53) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL696853 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL3142619 | 0.85 | TYK2 (0.55) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL295414 | 0.85 | SMN1; SMN2 (0.57) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL18758272 | 0.83 | ALDH1A1 (0.44) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL2468448 | 0.83 | KDM4E (0.54) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL1180038 | 0.83 | TYK2 (0.57) | ALDH1A1HPGDMAPK1CYP3A4TYK2 | |
| SCHEMBL3032507 | 0.83 | TYK2 (0.54) | ALDH1A1HPGDMAPK1CYP3A4TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101107216-A | Process for the preparation of fenoldopam mesylate | SICOR INC (US) | 2008-01-16 | — | — | CN | claimed |
| CN-118026949-A | Thiazole histone deacetylase inhibitor and preparation method and application thereof | 济南大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-108602811-B | FXR receptor agonists | 轩竹生物科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-111333663-A | Cycloalkylthienopyrimidone compounds and preparation method and application thereof | 天津医科大学 | 2020-06-26 | — | — | CN | disclosed |
| CN-109748785-A | Two aromatic hydrocarbon substituted propenone class compounds of one kind and preparation method and application | 山东大学 | 2019-05-14 | — | — | CN | disclosed |
| WO-2017133521-A1 | FXR RECEPTOR AGONIST | 山东轩竹医药科技有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-20150239857-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2015-08-27 | — | — | US | disclosed |
| EP-1216996-A2 | Method to synthesise biphenylyl derivatives | SANOFI-SYNTHELABO (FR) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002042261-A2 | PROCESS FOR PREPARING α-(3-ARYLTHIO)-ACETOPHENONES | ELI LILLY AND COMPANY (US) | 2002-05-30 | — | — | WO | disclosed |
| US-5837728-A | ACNE AND OTHER SKIN DISORDERS; ANTIAGING, ANTIWRINKLING AND WOUND HEALING AGENTS; SIDE EFFECT REDUCTION | MOLECULAR DESIGN INTERNATIONAL (US) | 1998-11-17 | — | — | US | disclosed |
| WO-1997032839-A9 | 9-CIS-RETINOIC ACID ESTERS AND AMIDES AND USES THEREOF | — | 1998-07-16 | — | — | WO | disclosed |
| EP-0837848-A1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI (FR) | 1998-04-29 | — | — | EP | disclosed |
| EP-0531715-B1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL CO (JP) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997001536-A1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI (FR) | 1997-01-16 | — | — | WO | disclosed |
| US-5426237-A | Oxidation of straight, branched or cyclic alkanes and benzene derivatives in presence of transition metal catalyst and aldehyde | SUMITOMO CHEMICAL CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
| EP-0531715-A1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
| EP-0020970-A1 | Alpha-chloroacetophenonoxime ethers and process for their preparation | BASF Aktiengesellschaft (DE) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239857-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | ALDH1A1 3506/4885HPGD 3985/4885MAPK1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.